Clinical Trial

Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective is to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody) combined with GemOX and lenvatinib as conversion therapy for Initially Potentially Resectable intrahepatic cholangiocarcinoma and gallbladder cancer.
Trial Details
NCT Number NCT07263360
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions BTC
Enrollment 29 participants
Start Date 2026-02-01
Primary Completion 2028-03-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-04